MORISE Masahiro

J-GLOBAL         Last updated: Nov 15, 2019 at 03:07
 
Avatar
Name
MORISE Masahiro
E-mail
morisemmed.nagoya-u.ac.jp
Affiliation
Nagoya University
Section
Nagoya University Hospital Respiratory Medicine
Job title
Lecturer of hospital
Research funding number
00612756

Academic & Professional Experience

 
Apr 2011
 - 
Mar 2014
Assistant professor of hospital, Nagoya University Hospital, Nagoya University
 
Apr 2014
 - 
Dec 2014
Assistant professor of hospital, Nagoya University Hospital Respiratory Medicine, Nagoya University
 
Jan 2015
 - 
Jan 2017
Assistant professor of hospital, Nagoya University Hospital Center for Postgraduate Clinical Training and Career Development, Nagoya University
 
Feb 2017
 - 
Mar 2019
Assistant professor of hospital, Nagoya University Hospital, Nagoya University
 
Feb 2017
 - 
Mar 2019
Postgraduate Clinical Training and Career Development Support Center, Deputy Director, Nagoya University Hospital, Nagoya University
 

Education

 
 
 - 
Mar 2000
Faculty of Medicine, Gifu University
 
 
 - 
Mar 2010
Graduate School, Division of Medical Sciences, Nagoya University
 

Published Papers

 
Can we predict the development of serious adverse events (SAEs) and early treatment termination in elderly non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy?
Kato T, Morise M (equal first author), Ando M, Kojima E, Ogasawara T, Suzuki R, Shindoh J, Matsumoto M, Sugino Y, Ogawa M, Nozaki Y, Hase T, Kondo M, Saito H, Hasegawa Y
Can we predict the development of serious adverse events (SAEs) and early treatment termination in elderly non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy?   142(7) 1629-40   2016   [Refereed]
Akamatsu H, Ninomiya K, Kenmotsu H, Morise M, Daga H, Goto Y, Kozuki T, Miura S, Sasaki T, Tamiya A, Teraoka S, Tsubata Y, Yoshioka H, Hattori Y, Imamura CK, Katsuya Y, Matsui R, Minegishi Y, Mizugaki H, Nosaki K, Okuma Y, Sakamoto S, Sone T, Tanaka K, Umemura S, Yamanaka T, Amano S, Hasegawa K, Morita S, Nakajima K, Maemondo M, Seto T, Yamamoto N
International journal of clinical oncology      May 2019   [Refereed]
Tanaka Ichidai, Morise Masahiro, Kodama Yuta, Matsui Akira, Ozawa Naoya, Ozone Sachiko, Goto Daiki, Miyazawa Ayako, Hase Tetsunari, Hashimoto Naozumi, Sato Mitsuo, Hasegawa Yoshinori
LUNG CANCER   127 169-171   Jan 2019   [Refereed]
Sato M, Matsui A, Shimoyama Y, Omote N, Morise M, Hase T, Tanaka I, Suzuki K, Hasegawa Y
Internal medicine (Tokyo, Japan)      Aug 2018
Tanaka Ichidai, Sato Mitsuo, Kato Toshio, Goto Daiki, Kakumu Tomohiko, Miyazawa Ayako, Yogo Naoyuki, Hase Tetsunari, Morise Masahiro, Sekido Yoshitaka, Girard Luc, Minna John D., Byers Lauren A., Heymach John V., Coombes Kevin R., Kondo Masashi, Hasegawa Yoshinori
CANCER SCIENCE   109(6) 1843-1852   Jun 2018

Misc

 
Can we predict the development of serious adverse events (SAEs) and early treatment termination in elderly non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy?
Kato T, Morise M (equal first author), Ando M, Kojima E, Ogasawara T, Suzuki R, Shindoh J, Matsumoto M, Sugino Y, Ogawa M, Nozaki Y, Hase T, Kondo M, Saito H, Hasegawa Y
Can we predict the development of serious adverse events (SAEs) and early treatment termination in elderly non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy?   142(7) 1629-40   2016   [Refereed]
Sato M, Matsui A, Shimoyama Y, Omote N, Morise M, Hase T, Tanaka I, Suzuki K, Hasegawa Y
Internal medicine (Tokyo, Japan)      Aug 2018
Tanaka Ichidai, Sato Mitsuo, Kato Toshio, Goto Daiki, Kakumu Tomohiko, Miyazawa Ayako, Yogo Naoyuki, Hase Tetsunari, Morise Masahiro, Sekido Yoshitaka, Girard Luc, Minna John D., Byers Lauren A., Heymach John V., Coombes Kevin R., Kondo Masashi, Hasegawa Yoshinori
CANCER SCIENCE   109(6) 1843-1852   Jun 2018
Okachi Shotaro, Imaizumi Kazuyoshi, Imai Naoyuki, Shimizu Takahiro, Hase Tetsunari, Morise Masahiro, Hashimoto Naozumi, Sato Mitsuo, Hasegawa Yoshinori
EUROPEAN GERIATRIC MEDICINE   9(2) 255-262   Apr 2018
Shintani Yasushi, Hasegawa Seiki, Takuwa Teruhisa, Aoe Keisuke, Kato Katsuya, Fujimoto Nobukazu, Hida Yasuhiro, Morise Masahiro, Moriya Yasumitsu, Morohoshi Takao, Okumura Meinoshin, Yoshino Ichiro
JOURNAL OF THORACIC DISEASE   10(3) 1968-1971   Mar 2018

Conference Activities & Talks

 
The indication of primary prevention for febrile neutropenia (FN) in elderly NSCLC patients treated with docetaxel.
Morise M, Kondo M, Hasegawa Y.
2016 the Japanese Society of Medical Oncology Annual Meeting   28 Jul 2016   
The efficacy and safety of re-challenge platinum plus pemtrexed combination therapy for recurrent malignant pleural mesothelioma
Mariko Morishita, Masahiro Morise, Tetsunari Hase, Mitsuo Sato, Masashi Kondoh, Yoshinori Hasegawa.
16th World Conference on Lung Cancer   Sep 2015   
Clinicopathological analysis of SRE in patients with SCLC and NSCLC
Morise M, Kondo M, Hasegawa Y
Japan Society of Medical Oncology Annual meeting 2015   Jul 2015   
The prophylactic antiemetic treatment failure in patients with lung cancer treated with CBDCA based-chemotherapy
Ichikawa K, Morise M, Miyazaki M, Hase T, Kondo M, Hasegawa Y, Yamada K
Japan Society of Medical Oncology Annual meeting 2015   Jul 2015   
Can we predict serious adverse events (SAEs) and clarify unfit population for platinum-based chemotherapy in elderly patients (over 70 years of age) with advanced Non-small cell lung cancer (NSCLC)? (CJLSG 1203 trial)
Kato T, Morise M, Ando M, Kojima E, Ogasawara T, Suzuki R, Shindo J, Matsumoto M, Sugino Y, Ogawa M, Nozaki Y, Kondo M, Saito H, Hasegawa Y.
European Society of Medical Oncology Annual meeting 2014   Sep 2014